Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • GSK, other drugmakers...

    GSK, other drugmakers bet on post-Brexit UK science

    Written by Ruby Khatun Khatun Published On 2017-12-07T09:30:35+05:30  |  Updated On 7 Dec 2017 9:30 AM IST
    GSK, other drugmakers bet on post-Brexit UK science

    LONDON: Britain won a vote of confidence from its economically important life sciences sector on Wednesday as five drug companies committed to invest in the country under the government’s industrial strategy plans after Brexit.


    The move is welcome news for Prime Minister Theresa May, who has struggled to win over large sections of the industry as Britain prepares to leave the European Union.


    Thanks to the strength of UK universities and the presence of two major pharmaceuticals companies in GlaxoSmithKline and AstraZeneca, the drugs industry has been a bright spot in the British economy for many years.



    But the highly regulated sector faces potential obstacles to trade as a result of Brexit unless London and Brussels manage to align regulatory regimes for medicines.

    In a bid to soften the blow, the government has backed a report by immunologist and geneticist John Bell designed to boost the pharmaceutical sector via fresh public-private collaborations.


    That has paved the way for the Life Sciences Sector Deal, which will see GSK invest 40 million pounds ($54 million) of new money in genomic research, including a plan to sequence DNA from all 500,000 volunteer participants enrolled in UK Biobank, the world’s most detailed biomedical database.


    GSK’s head of research Patrick Vallance said the deal showed Britain remained an attractive place for drug discovery, but he cautioned: “The UK needs to recognize going forward that science is an international endeavor, not a parochial endeavor.”


    Other investments include plans by Johnson & Johnson and the Medicines Co to work on new clinical trials, and genetic research by AstraZeneca.


    U.S. drugmaker Merck & Co had already announced plans to expand UK research operations under the deal last week.




    (Reporting by Ben Hirschler; Editing by Gareth Jones)



    AstraZenecaBrexitDrugmakersEuropean Uniongenomic researchGlaxoSmithKlineGSKJohnson and JohnsonMerckPatrick Vallancepharma newsTheresa MayUK science
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok